

**Contacts:** Jane Braden, Inoveon  
(405) 715-3232, [jane@goodengroup.com](mailto:jane@goodengroup.com)  
Dana Berry, CU-Health Sciences Center  
(303) 315-5571, [dana.berry@uchsc.edu](mailto:dana.berry@uchsc.edu)

## **Inoveon To Offer Diabetic Retinopathy Evaluation Services to One of the Nation's Leading Juvenile Diabetes Centers**

### ***The Barbara Davis Center for Childhood Diabetes in Denver to Become an Inoveon iSite***

Sept. 8, 2004 (OKLAHOMA CITY, OKLA.) — Inoveon Corp., the industry leader in detection, staging and monitoring of diabetic retinopathy, today announced that it has entered into a multi-year agreement with the Barbara Davis Center for Childhood Diabetes in Denver. In conjunction with the Barbara Davis Center, Inoveon will open an iSite imaging center featuring Inoveon's proprietary diabetic retinopathy imaging system for early detection, staging and monitoring of diabetic eye disease. The actual procedure is referred to as an iScan.

"Inoveon is proud to have the opportunity to work closely with such a prestigious center to help them manage this potentially devastating eye disease in their young patient population," said Terry Crabtree, Inoveon president & CEO. "Our relationship with the Barbara Davis Center builds on our mission to deliver the highest quality systems and services to detect, stage and monitor diabetic retinopathy."

Diabetic retinopathy is the leading cause of preventable blindness in the U.S. Use of the iScan imaging procedure leads to early intervention, improved outcomes and avoidance of expensive invasive procedures for patients.

"Inoveon's iSite will significantly elevate our ability to red flag and manage diabetic retinopathy complications in the children and young adults we serve," noted Dr. George Eisenbarth, executive director, Barbara Davis Center for Childhood Diabetes. "The leading edge quality and efficiencies the Inoveon service offers is a perfect fit with our mission to embrace the latest breakthroughs in diabetic care for our patients. We look for technology that allows us to focus on results that can be measured, documented and improve patient care through quality clinical programs; Inoveon's iScan certainly meets those criteria."

Inoveon's iScan technology delivers the National Institutes of Health gold standard of care technology using high-resolution, seven-field, color retinal imaging to evaluate and monitor diabetic retinopathy and effectively identify

(more)

patients in need of specialized care. The iScan achieved 98.2 percent sensitivity and 89.7 percent specificity for detection of vision threatening diabetic retinopathy when compared with the gold standard film-based approach.

“Providers using the iScan service tell us they have shown significant improvements in patient compliance with recommended annual dilated retinal evaluations and very high levels of patient satisfaction,” Crabtree continued. “We have the most clinical experience in the country with more than 29,000 cases. Our system increases patient compliance, produces outstanding patient satisfaction and seamlessly integrates into high volume medical practices.”

Patients taking the iScan test simply look into the camera and the technician takes images of their retina. Those digital images are sent via the Internet to Inoveon’s national reading center where highly qualified technicians “read” the image to evaluate the condition of the retina. The patient’s physician then receives a numeric report indicating whether disease is present and if present, the stage of the disease. The managing physician can then better manage the patient’s care.

**About Barbara Davis Center for Childhood Diabetes:**

The Barbara Davis Center for Childhood Diabetes of the University of Colorado at Denver and Health Sciences Center is the largest pediatric diabetes facility in the country. The Center’s mission is to provide care for children and adults with type 1 diabetes in a unique environment that fosters clinical and basic biomedical research. The development and application of research for the prevention, cure and understanding of diabetes will take place under one roof — the first two levels of the building will be used for clinical care and the upper two levels for research. The center was founded in 1977 and provides clinical diabetes care to 5,000 children and young adults from Colorado and worldwide. For more information, visit: [www.barbaradaviscenter.org](http://www.barbaradaviscenter.org) or [www.childrensdiabetesfdn.org](http://www.childrensdiabetesfdn.org).

The University of Colorado at Denver and Health Sciences Center is one of three campuses in the University of Colorado system. Located in Denver and Aurora, Colo., the center includes schools of medicine, nursing, pharmacy, and dentistry, a graduate school and a teaching hospital. For more information, visit the Web site at [www.uchsc.edu](http://www.uchsc.edu).

**About Inoveon:**

Inoveon Corp. is the industry leader in the detection, staging and monitoring of diabetic retinopathy. Founded in 1997, Inoveon Corp. has successfully completed more than 29,000 clinical iScan retinal imaging studies. The service is delivered in partnership with large primary care and endocrinology clinics to improve the quality, economics, and medical outcomes of patients at risk for vision loss due to diabetes. Placing the service in the primary care environment helps to increase patient compliance with recommended annual dilated retinal evaluations and provides clinically rich information to improve patient care. For more information, visit the Web site at [www.inoveon.com](http://www.inoveon.com).